Free Trial

Fresenius SE & Co. (OTCMKTS:FSNUY) Hits New 1-Year Low - What's Next?

Fresenius SE & Co. logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Fresenius hit a new 52-week low of $11.54, trading down about 2.9% on the day with roughly 25,412 shares changing hands, while its 50‑day ($13.27) and 200‑day ($14.19) moving averages remain above the current price.
  • Analysts still maintain a Buy consensus (three buy ratings), with Morgan Stanley reiterating an "overweight" and Citigroup a "buy."
  • Recent fundamentals show a market cap of about $26.2B and a PE of 18.46; the company reported $0.28 EPS on $6.94B revenue for the quarter, and sell‑side analysts expect roughly $1.05 EPS for the year.
  • Five stocks to consider instead of Fresenius SE & Co..

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report)'s share price reached a new 52-week low on Tuesday . The stock traded as low as $11.54 and last traded at $11.54, with a volume of 25412 shares changing hands. The stock had previously closed at $11.98.

Analyst Ratings Changes

FSNUY has been the subject of several research reports. Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a research note on Monday, April 20th. Citigroup restated a "buy" rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy".

View Our Latest Stock Report on FSNUY

Fresenius SE & Co. Trading Down 2.9%

The firm has a market capitalization of $26.20 billion, a PE ratio of 18.46 and a beta of 0.68. The company's 50-day moving average price is $13.27 and its 200-day moving average price is $14.19. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.00 and a current ratio of 1.32.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. The business had revenue of $6.94 billion during the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.31%. On average, sell-side analysts expect that Fresenius SE & Co. will post 1.05 earnings per share for the current year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fresenius SE & Co. Right Now?

Before you consider Fresenius SE & Co., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. wasn't on the list.

While Fresenius SE & Co. currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines